Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Mineralys Therapeutics, Inc. (MLYS : NSDQ)

• Company Description    Mineralys Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Mineralys Therapeutics Inc. is based in RADNOR, Pa. Number of Employees: 76

• Price / Volume Information    Yesterday's Closing Price: $29.85 Daily Weekly Monthly 20 Day Moving Average: 1,172,680 shares Shares Outstanding: 82.50 (millions) Market Capitalization: $2,462.57 (millions) Beta: 0.49 52 Week High: $47.65 52 Week Low: $12.59 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 4.77% -0.34% 12 Week 2.82% -4.94% Year To Date -17.75% -23.41%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 150 N. RADNOR CHESTER ROAD SUITE F200 - RADNOR,PA 19087 USA ph: 888-378-6240 fax: - investorrelations@mineralystx.com http://www.mineralystx.com

• General Corporate Information    Officers Jon Congleton - Chief Executive Officer Glenn Sblendorio - Chairman Adam Levy - Chief Financial Officer and Secretary Srinivas Akkaraju - Director Derek DiRocco - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 603170101 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/11/26 Share - Related Items Shares Outstanding: 82.50 Most Recent Split Date: (:1) Beta: 0.49 Market Capitalization: $2,462.57 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.54 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.30 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.86 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 40.51% vs. Previous Quarter: -17.50% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -27.92 12/31/25 - -32.94 09/30/25 - -48.18 ROA 03/31/26 - -26.98 12/31/25 - -31.68 09/30/25 - -45.80 Current Ratio 03/31/26 - 44.33 12/31/25 - 43.76 09/30/25 - 25.50 Quick Ratio 03/31/26 - 44.33 12/31/25 - 43.76 09/30/25 - 25.50 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 7.74 12/31/25 - 8.17 09/30/25 - 8.69 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©